SE9702860L - Användning av en stam av Lactobacillus för tillverkning av ett läkemedel för reduktion av fibrinogenhalten i blod - Google Patents

Användning av en stam av Lactobacillus för tillverkning av ett läkemedel för reduktion av fibrinogenhalten i blod

Info

Publication number
SE9702860L
SE9702860L SE9702860A SE9702860A SE9702860L SE 9702860 L SE9702860 L SE 9702860L SE 9702860 A SE9702860 A SE 9702860A SE 9702860 A SE9702860 A SE 9702860A SE 9702860 L SE9702860 L SE 9702860L
Authority
SE
Sweden
Prior art keywords
lactobacillus
strain
blood
manufacture
drug
Prior art date
Application number
SE9702860A
Other languages
English (en)
Other versions
SE510753C2 (sv
SE9702860D0 (sv
Inventor
Hanna Bukowska
Merek Naruszewicz
Marie-Louise Johansson
Original Assignee
Probi Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probi Ab filed Critical Probi Ab
Priority to SE9702860A priority Critical patent/SE510753C2/sv
Publication of SE9702860D0 publication Critical patent/SE9702860D0/sv
Priority to ZA986769A priority patent/ZA986769B/xx
Priority to BR9811825-0A priority patent/BR9811825A/pt
Priority to NZ502610A priority patent/NZ502610A/xx
Priority to IL13411398A priority patent/IL134113A0/xx
Priority to AT98934131T priority patent/ATE326524T1/de
Priority to DE69834560T priority patent/DE69834560T2/de
Priority to KR10-2000-7001211A priority patent/KR100517755B1/ko
Priority to JP2000506312A priority patent/JP4651814B2/ja
Priority to PL98338578A priority patent/PL194697B1/pl
Priority to US09/485,190 priority patent/US6214336B1/en
Priority to EP98934131A priority patent/EP0990024B1/en
Priority to CA2297023A priority patent/CA2297023C/en
Priority to ES98934131T priority patent/ES2259457T3/es
Priority to PCT/SE1998/001423 priority patent/WO1999007827A1/en
Priority to AU83726/98A priority patent/AU729413B2/en
Priority to CNB988076357A priority patent/CN1142995C/zh
Priority to ARP980103872A priority patent/AR016798A1/es
Publication of SE9702860L publication Critical patent/SE9702860L/sv
Publication of SE510753C2 publication Critical patent/SE510753C2/sv
Priority to NO20000268A priority patent/NO324881B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus
    • Y10S435/856—Lactobacillus casei
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus
    • Y10S435/857—Lactobacillus plantarum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SE9702860A 1997-08-05 1997-08-05 Användning av en stam av Lactobacillus för tillverkning av ett läkemedel för reduktion av fibrinogenhalten i blod SE510753C2 (sv)

Priority Applications (19)

Application Number Priority Date Filing Date Title
SE9702860A SE510753C2 (sv) 1997-08-05 1997-08-05 Användning av en stam av Lactobacillus för tillverkning av ett läkemedel för reduktion av fibrinogenhalten i blod
ZA986769A ZA986769B (en) 1997-08-05 1998-07-29 Reduction of the fibrinogen level
CNB988076357A CN1142995C (zh) 1997-08-05 1998-07-30 乳杆菌属菌株在降低血液纤维蛋白原水平中的应用
JP2000506312A JP4651814B2 (ja) 1997-08-05 1998-07-30 血中のフィブリノーゲン・レベルを低下させるためのラクトバシラスの使用
EP98934131A EP0990024B1 (en) 1997-08-05 1998-07-30 Use of lactobacillus for reduction of the fibrinogen level in blood
IL13411398A IL134113A0 (en) 1997-08-05 1998-07-30 Use of lactobacillus for reduction of the fibrinogen level in blood
AT98934131T ATE326524T1 (de) 1997-08-05 1998-07-30 Verwendung von lactobacillus zur verminderung des fibrinogengehalts im blut
DE69834560T DE69834560T2 (de) 1997-08-05 1998-07-30 Verwendung von lactobacillus zur verminderung des fibrinogengehalts im blut
KR10-2000-7001211A KR100517755B1 (ko) 1997-08-05 1998-07-30 락토바실러스를 혈액내 피브리노겐 레벨의 감소용으로 사용하는 용도
BR9811825-0A BR9811825A (pt) 1997-08-05 1998-07-30 Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue
PL98338578A PL194697B1 (pl) 1997-08-05 1998-07-30 Zastosowanie szczepu Lactobacillus
US09/485,190 US6214336B1 (en) 1997-08-05 1998-07-30 Use of lactobacillus for reduction of the fibrinogen level in blood
NZ502610A NZ502610A (en) 1997-08-05 1998-07-30 Use of lactobacillus for reduction of the fibrinogen level in blood
CA2297023A CA2297023C (en) 1997-08-05 1998-07-30 Use of lactobacillus for reduction of the fibrinogen level in blood
ES98934131T ES2259457T3 (es) 1997-08-05 1998-07-30 Uso de lactobacilus para reducir el nivel de fibrinogeno en sangre.
PCT/SE1998/001423 WO1999007827A1 (en) 1997-08-05 1998-07-30 Use of lactobacillus for reduction of the fibrinogen level in blood
AU83726/98A AU729413B2 (en) 1997-08-05 1998-07-30 Use of lactobacillus for reduction of the fibrinogen level in blood
ARP980103872A AR016798A1 (es) 1997-08-05 1998-08-05 Uso de una cepa de lactobacillus para la elaboracion de un medicamento
NO20000268A NO324881B1 (no) 1997-08-05 2000-01-19 Anvendelse av en stamme av Lactobacillus for fremstilling av et medikament for profylakse og/eller behandling av sirkulatoriske sykdommer.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9702860A SE510753C2 (sv) 1997-08-05 1997-08-05 Användning av en stam av Lactobacillus för tillverkning av ett läkemedel för reduktion av fibrinogenhalten i blod

Publications (3)

Publication Number Publication Date
SE9702860D0 SE9702860D0 (sv) 1997-08-05
SE9702860L true SE9702860L (sv) 1999-02-06
SE510753C2 SE510753C2 (sv) 1999-06-21

Family

ID=20407874

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9702860A SE510753C2 (sv) 1997-08-05 1997-08-05 Användning av en stam av Lactobacillus för tillverkning av ett läkemedel för reduktion av fibrinogenhalten i blod

Country Status (19)

Country Link
US (1) US6214336B1 (sv)
EP (1) EP0990024B1 (sv)
JP (1) JP4651814B2 (sv)
KR (1) KR100517755B1 (sv)
CN (1) CN1142995C (sv)
AR (1) AR016798A1 (sv)
AT (1) ATE326524T1 (sv)
AU (1) AU729413B2 (sv)
BR (1) BR9811825A (sv)
CA (1) CA2297023C (sv)
DE (1) DE69834560T2 (sv)
ES (1) ES2259457T3 (sv)
IL (1) IL134113A0 (sv)
NO (1) NO324881B1 (sv)
NZ (1) NZ502610A (sv)
PL (1) PL194697B1 (sv)
SE (1) SE510753C2 (sv)
WO (1) WO1999007827A1 (sv)
ZA (1) ZA986769B (sv)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2345110A1 (en) * 1998-10-01 2000-04-13 Probi Ab Reduction of oxidative stress factors
JP4193269B2 (ja) * 1999-03-04 2008-12-10 ビーエイチピーエイチ カンパニーリミテッド 新規な生体浄化活性型乳酸菌製剤
SE523771C2 (sv) * 1999-05-21 2004-05-18 Probi Ab Sportdryck innehållande mikronäringsämnen i kombination med levande laktobaciller
AUPR101600A0 (en) * 2000-10-25 2000-11-16 Atheromastat Pty Ltd Compositions and methods for diagnosis and treatment of cardiovascular disorders
SE0004124D0 (sv) * 2000-11-10 2000-11-10 Probi Ab New use
GB0124580D0 (en) * 2001-10-12 2001-12-05 Univ Reading New composition
KR20030033950A (ko) * 2001-10-20 2003-05-01 주식회사 알엔에이 유산균 세포질 분획물 또는 유산균 파쇄물을 유효성분으로포함하는 동맥경화 억제제
FR2831395B1 (fr) * 2001-10-25 2004-06-11 Triballat Laiteries Procede de fabrication de produits fermentes a base de soja, produits fermentes obtenus par ce procede et ferments correspondants
TWI241912B (en) * 2002-10-30 2005-10-21 Food Industry Res & Dev Inst Novel Acid-and bile salt-resistant Lactobacillus isolates having the ability to lower and assimilate cholesterol
SE527555C2 (sv) * 2003-04-04 2006-04-11 Probi Ab Anti-inflammatorisk komposition innehållande tannasproducerande Lactobacillusstammar
CN1207382C (zh) * 2003-04-11 2005-06-22 上海光明乳业股份有限公司 植物乳杆菌st－iii菌株及其在调节血脂方面的应用
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US7001756B1 (en) * 2004-02-19 2006-02-21 Genmont Biotech Inc. Microorganism strain of GM-020 of Lactobacillus rhamnosus and its use for treating obesity
GB0424552D0 (en) * 2004-11-05 2004-12-08 Cambridge Theranostics Ltd Methods and means
EP1880001B1 (en) 2005-05-31 2011-06-08 The Iams Company Feline probiotic lactobacilli
JP4938006B2 (ja) 2005-05-31 2012-05-23 ザ・アイムス・カンパニー ネコ科動物プロバイオティク・ビフィドバクテリア
US20080254011A1 (en) * 2007-04-11 2008-10-16 Peter Rothschild Use of selected lactic acid bacteria for reducing atherosclerosis
KR100909586B1 (ko) * 2007-06-01 2009-07-27 신현길 혈중 콜레스테롤 농도 저하에 효과적인 유산균 및 이들의혼합균주
SE532899C2 (sv) * 2007-06-08 2010-05-04 Probi Ab Förfarande genom fermentering med Lactobacillus plantarum för tillhandahållande av en insulinsvarsreducerande produkt och dess användning farmaceutiskt eller i livsmedel
JP5469873B2 (ja) * 2008-03-11 2014-04-16 株式会社日立製作所 回転電機
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
JP5140791B2 (ja) * 2008-11-27 2013-02-13 森下仁丹株式会社 乳酸菌含有血中ホモシステイン低減剤
US9474773B2 (en) 2009-02-18 2016-10-25 University Of Florida Research Foundation, Inc. Lactobacillus supplement for alleviating type 1 diabetes
ES2729765T3 (es) * 2009-06-19 2019-11-06 Dupont Nutrition Biosci Aps Bifidobacterias para el tratamiento de la insuficiencia cardíaca congestiva
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
CN102031229B (zh) * 2009-09-24 2012-05-30 家医国际生化股份有限公司 具有肠胃道吸附能力及排除胆固醇能力的植物乳杆菌
CN102858948B (zh) * 2010-01-08 2015-11-25 热尔韦·达诺尼公司 具有抗氧化作用的乳酸杆菌
GB201319538D0 (en) 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition
GB201319540D0 (en) * 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition
GB201709763D0 (en) * 2017-06-19 2017-08-02 Probi Ab Biological materials and methods
CN110786435B (zh) * 2019-11-19 2022-08-23 四川农业大学 产高活性纤溶酶原激活剂的植物乳杆菌及用其发酵的果蔬汁饮料

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0647551B2 (ja) * 1986-12-01 1994-06-22 株式会社ヤクルト本社 血圧降下剤
JP2676250B2 (ja) * 1989-03-20 1997-11-12 株式会社ヤクルト本社 血圧降下剤およびその製造法
JP2855290B2 (ja) * 1990-11-30 1999-02-10 株式会社ヤクルト本社 脂質代謝改善剤
JPH04264034A (ja) * 1991-02-18 1992-09-18 Snow Brand Milk Prod Co Ltd 生体内過酸化脂質抑制剤
JPH0525055A (ja) * 1991-07-22 1993-02-02 Yakult Honsha Co Ltd 血圧降下剤
SE469875C (sv) * 1991-07-25 1997-04-14 Probi Ab Stam av tarmkoloniserande Lactobacillus samt komposition för profylax eller behandling av infektioner i magtarmkanalen
JPH06116155A (ja) * 1992-10-08 1994-04-26 Yakult Honsha Co Ltd 血清コレステロール低下剤
JP2801479B2 (ja) * 1992-10-09 1998-09-21 株式会社トクヤマ 補綴材料の製造方法
JP2992945B2 (ja) * 1994-03-11 1999-12-20 カルピス株式会社 ラクトバチルス・アシドフィルス乳酸菌
JPH08208512A (ja) * 1995-02-03 1996-08-13 Nippon Chem Res Kk 血栓形成阻害剤

Also Published As

Publication number Publication date
IL134113A0 (en) 2001-04-30
SE510753C2 (sv) 1999-06-21
EP0990024A1 (en) 2000-04-05
CA2297023C (en) 2010-03-30
KR100517755B1 (ko) 2005-09-30
US6214336B1 (en) 2001-04-10
AU8372698A (en) 1999-03-01
NO20000268D0 (no) 2000-01-19
KR20010022617A (ko) 2001-03-26
NO324881B1 (no) 2007-12-27
CN1265141A (zh) 2000-08-30
AR016798A1 (es) 2001-08-01
CA2297023A1 (en) 1999-02-18
EP0990024B1 (en) 2006-05-17
ES2259457T3 (es) 2006-10-01
ZA986769B (en) 1999-02-02
BR9811825A (pt) 2000-08-15
DE69834560D1 (de) 2006-06-22
DE69834560T2 (de) 2006-11-02
JP2001512747A (ja) 2001-08-28
WO1999007827A1 (en) 1999-02-18
NO20000268L (no) 2000-01-19
PL194697B1 (pl) 2007-06-29
AU729413B2 (en) 2001-02-01
CN1142995C (zh) 2004-03-24
SE9702860D0 (sv) 1997-08-05
PL338578A1 (en) 2000-11-06
JP4651814B2 (ja) 2011-03-16
NZ502610A (en) 2000-12-22
ATE326524T1 (de) 2006-06-15

Similar Documents

Publication Publication Date Title
SE9702860L (sv) Användning av en stam av Lactobacillus för tillverkning av ett läkemedel för reduktion av fibrinogenhalten i blod
WO2001049236A3 (en) Method and system for treating cardiac arrest
WO2001012122A3 (en) Method and system for treating cardiac arrest using hypothermia
ES2077530A1 (es) Procedimiento para la preparacion de productos farmaceuticos para curar enfermedades tumorales.
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
ATE312635T1 (de) Ventilanordnung
IL171607A (en) Use of botulinum toxin for the treatment of sinusitis-induced headaches
ID24901A (id) Metode pengobatan keadaan terkoagulasi tinggi atau defisiensi protein c yang diperoleh
HK1130422A1 (en) A new use of deferiprone
FI964332A (sv) Användning av vissa metanbisfofonsyraderivat för att hindra förslappning och vandring av protes
ATE405277T1 (de) Substitutions-infusionflüssigkeit und zitratanticoagulation
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
DE60115432D1 (de) Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
IL143824A0 (en) New dialysis method
MD990258A (en) Method of treatment of the acute viral hepatitis B
GB0020504D0 (en) Therapeutic method
MD545G2 (ro) Preparat medicamentos
NZ514911A (en) Use of N-acetylcysteine for the preparation of a medicament suitable for the intravenous administration to prevent oxidative stress in dialysed patients
IL159770A0 (en) Calcium salts with cytotoxic activity
PT1150981E (pt) Composto nucleosidico terapeutico
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
EP1143981A4 (en) TREATMENT AND PREVENTION OF HIV AND OTHER VIRUS INFECTIONS
UA31131A (uk) Спосіб прогнозування післяопераційного перебігу інфекційного ендокардиту
HK1003422A1 (en) A method of treating liver disease and like indications with vasodilating agents
UA36361A (uk) Спосіб лікування захворювань щитовидної залози

Legal Events

Date Code Title Description
NUG Patent has lapsed